Compare Natera Inc. Common Stock (NTRA) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $59.22 (market cap $3.38B). The key difference: Natera Inc. Common Stock is far larger — about 16.9× SP Funds S&P 500 Sharia Industry Exclusions ETF's market cap, and SP Funds S&P 500 Sharia Industry Exclusions ETF is more actively traded (308,295 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and SP Funds S&P 500 Sharia Industry Exclusions ETF for 66 Days on average.
| NTRA | SPUS | |
|---|---|---|
Market Cap | $57.03B | $3.38B |
Volume | 1,131,157 | 308,295 |
Sector | Health | Broad Market / Factor |
52-Week High | $425.64 | $61.15 |
52-Week Low | $179.42 | $46.65 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SPUS trades at $60.53, showing minimal daily movement with a slight decline of 0.07%. Technical indicators signal a bullish trend with strong moving average support, though oscillators remain neutral. The ETF maintains regular dividend distributions, with recent payments of $0.03 per share. Short interest saw significant growth in September, increasing 174.5% to 257,142 shares as of September 15, 2026.
The ETF's technical strength supports near-term upside potential, though elevated short interest indicates some bearish sentiment. Dividend consistency provides income appeal, but investors should monitor the growing short position which could increase volatility. The neutral oscillator readings suggest potential consolidation before further directional movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
